Cardiol Therapeutics Inc. has announced a new at-the-market equity offering program in partnership with Jefferies LLC, allowing the company to raise up to $75 million. This strategic move is aimed at funding the development of its therapies for heart disease, particularly CardiolRx™ for recurrent pericarditis, and supporting ongoing clinical trials.

The announcement, made on November 3, 2026, is significant as it reflects Cardiol's commitment to advancing its innovative treatments in a competitive market. The at-the-market (ATM) program enables the company to sell its common shares directly to the public through the Nasdaq Capital Market at prevailing market prices, providing flexibility in capital raising.

Background

Cardiol Therapeutics Inc. is a late-stage life sciences company focused on the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The company trades on the Nasdaq under the ticker CRDL and is classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). Recent filings include several 6-K reports and a Schedule 13G/A, indicating ongoing activity in the financial markets.

What the Filing Says

According to the filing, "The ATM Agreement will allow the Company to offer and sell up to US$75 million of common shares... The Offered Shares may be offered and sold by the Company to the public from time to time, through the Sales Agent." This program is designed to support the clinical development of Cardiol's therapies and cover general administrative expenses.

Impact

The ATM program could significantly impact Cardiol's funding strategy, allowing the company to access capital as needed without the constraints of traditional financing methods. This approach may also influence competitors in the biological products industry, encouraging them to explore similar flexible financing options to support their research and development initiatives.

What's Next

The filing does not say what happens next, but the company has indicated that the timing and extent of the use of the ATM Program will be at its discretion. Cardiol has no obligation to sell any shares, and total gross proceeds could be less than the $75 million targeted.